Akebia Therapeutics
Clinical trials sponsored by Akebia Therapeutics, explained in plain language.
Biopharmaceutical company focused on kidney disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug AKB-9090 takes first steps in human safety trial Results expected Dec 2026 (estimated)
- New hope for FSGS: experimental drug enters Mid-Stage trial Results expected Jun 2027 (estimated)
-
New hope for FSGS: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…
Phase 2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental drug aims to protect kidneys in inflammatory diseases
Disease control Recruiting nowThis study tests an experimental drug called ADX-097 in people aged 16 and older with three kidney conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The drug is given as an injection under the skin and is designed to reduce inflammation and protein leakage in t…
Phase 2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug AKB-9090 takes first steps in human safety trial
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, AKB-9090, in about 70 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, given through a vein, in either a single dose or multiple doses over time. The main goal …
Phase 1 • Sponsor: Akebia Therapeutics • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC